IP Verse

Pharmaceutical Formulations Of Bruton'S Tyrosine Kinase Inhibtor - EP3265084

The patent EP3265084 was granted to Pharmacyclics on Nov 22, 2023. The application was originally filed on Mar 2, 2016 under application number EP16759417A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3265084

PHARMACYCLICS
Application Number
EP16759417A
Filing Date
Mar 2, 2016
Status
Granted And Under Opposition
Oct 20, 2023
Grant Date
Nov 22, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSAug 21, 2024VON KAUFFMANNADMISSIBLE

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2013338172
DESCRIPTIONUS4327725
DESCRIPTIONUS4624848
DESCRIPTIONUS4968509
DESCRIPTIONUS5323907
DESCRIPTIONUS5456923
DESCRIPTIONUS5461140
DESCRIPTIONUS5516527
DESCRIPTIONUS5622721
DESCRIPTIONUS5686105
DESCRIPTIONUS5700410
DESCRIPTIONUS5977175
DESCRIPTIONUS6326469
DESCRIPTIONUS6465014
DESCRIPTIONUS6932983
DESCRIPTIONUS7514444
DESCRIPTIONUS7711492
EXAMINATIONWO2014004707
INTERNATIONAL-SEARCH-REPORTUS2012071497
INTERNATIONAL-SEARCH-REPORTUS2013338172
INTERNATIONAL-SEARCH-REPORTUS2014288037
INTERNATIONAL-SEARCH-REPORTUS2015031710
OPPOSITIONUS2013338172
OPPOSITIONWO2014004707
OPPOSITIONWO2015071432
OTHERWO2014004707
SEARCHUS2013338172
SEARCHWO2017125423
SEARCHWO2017125424

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Australian Public Assessment Report for ibrutinib", TGA Health Safety Regulation, (20160301), pages 1 - 83, XP093211000-
OPPOSITION- Anonymous, "CHMP assessment report - Imbruvica", European Medicines Agency, (20140724), pages 1 - 140, XP093211002-
OPPOSITION- Anonymous, "Introduction to Tableting by Wet Granulation", DFE pharma, (20140101), pages 1 - 10, XP093210603-
OPPOSITION- Raymond C Rowe , Paul J Sheskey , Marian E Quinn B, "Table of content", Raymond C Rowe , Paul J Sheskey , Marian E Quinn B, Raymond C Rowe , Paul J Sheskey , Marian E Quinn B, Handbook of Pharmaceutical Excipients, 6th Edition, London, Chicago, Pharmaceutical Press, American Pharmacists Association, (20090101), pages 1 - 5, ISBN 9780853697923, XP009559636-
OPPOSITION- E. Shotton , G. S. Leonard, "Effect of intragranular and extragranular disintegrating agents on particle size of disintegrated tablets", Journal of pharmaceutical sciences, (19760101), vol. 65, doi:10.1002/jps.2600650810, pages 1170 - 1174, XP009111167
OPPOSITION- M S Gordon , V S Rudraraju, K Dani, Z T Chowhan, "Effect of the mode of super disintegrant incorporation on dissolution in wet granulated tablets", Journal of Pharmaceutical Sciences, Wiley, United States, United States, (19930201), vol. 82, no. 2, doi:10.1002/jps.2600820222, ISSN 0022-3549, pages 220 - 226, XP001544057
OPPOSITION- Vít Zvoníček, Skořepová Eliška, Dušek Michal, Žvátora Pavel, Šoóš Miroslav, "Ibrutinib Polymorphs: Crystallographic Study", Crystal Growth & Design, US , (20180307), vol. 18, no. 3, doi:10.1021/acs.cgd.7b00923, ISSN 1528-7483, pages 1315 - 1326, XP055591027
OPPOSITION- Lu Jie, Rohani Sohrab, "Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)", Current medicinal chemistry, NL , (20090301), vol. 16, no. 7, doi:10.2174/092986709787549299, ISSN 0929-8673, pages 884 - 905, XP093210997

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents